Navigation Links
Medivation Presents New Data on Dimebon's Novel Mechanism of Action
Date:12/9/2008

al mechanism of action may account for the clinical benefit observed in the Dimebon Alzheimer's and Huntington's disease clinical trials completed to date.

About Dimebon

Dimebon is an oral small molecule in development with Pfizer for Alzheimer's and Huntington's diseases. It is currently being evaluated in a second pivotal Phase 3 trial in Alzheimer's disease. Results from the first pivotal trial were published in the July 19, 2008, edition of The Lancet. A Phase 2 study in Huntington's disease was recently completed, and further development is planned in Huntington's disease.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation entered into a global agreement with Pfizer Inc to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. With Pfizer, the Company is conducting a broad Dimebon clinical development program, including a pivotal and confirmatory Phase 3 trial, known as the CONNECTION study, in patients with mild-to-moderate Alzheimer's disease. The program also includes additional trials planned to begin next year in Alzheimer's disease, as well as further development of Dimebon in patients with mild-to-moderate Huntington's disease. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the mechanism of action of Dimebon, the p
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivation Announces Participation in RBC Capital Markets 2008 Healthcare Conference
2. Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update
3. Medivation Announces Third Quarter 2008 Teleconference and Webcast on November 10, 2008
4. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
5. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
6. Medivation Receives Corporate Achievement Award From Huntingtons Disease Society of America
7. Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for Dimebon
8. Medivation Announces Participation in Upcoming Conferences
9. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
10. Medivation Announces Second Quarter 2008 Teleconference and Webcast on August 11, 2008
11. Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
(Date:7/28/2014)... July 28, 2014 Immunomic Therapeutics, Inc. ... to further develop potential treatments for glioblastoma multiforme (GBM), ... combination with their patented vaccine platform, LAMP-vax. , ... are based on the work of John H. Sampson, ... The Preston Robert Tisch Brain Tumor Center at Duke ...
(Date:7/28/2014)...  InterMune, Inc. (NASDAQ: ITMN ) today ... financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. ... and others may participate in the conference call by ... replay of the webcast and teleconference will be available ...
(Date:7/25/2014)... "Ischemic Stroke and Cerebral Stroke ... on the Ischemic Stroke and Cerebral Stroke clinical ... data relating to the clinical trials on Ischemic ... Ischemic Stroke Research Report 2014 at: http://www.marketresearchreports.biz/analysis/213207 ... trial numbers and their recruitment status as per ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4InterMune to Release Second Quarter Financial Results on August 6 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3
... Divine Skin Inc. (DSKX) introduced a new molecule, Nanoxidil, designed ... surpass minoxidil for efficacy and tolerability. The innovative new compound ... weight is lower than that of minoxidil, a chemical on ... is a significant step forward in topical therapy, and we ...
... 2011 Jennerex, Inc., a private clinical-stage biotherapeutics ... first-in-class targeted oncolytic products for cancer, today announced ... using JX-594 to treat patients with metastatic melanoma ... Therapy . "This clinical trial ...
... store pictures, and edit all kinds of media formats are ... that is, bits and bytes. Modern computing technology is based ... as efficiently as possible. In a computer hard disk, this ... magnetic layer, where magnetic domains pointing "up" represent a "1" ...
Cached Biology Technology:Biotech Developer Divine Skin (DSKX) Debuts New Hair-Growth Molecule Nanoxidil 2Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma 2Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma 3Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma 4The art of magnetic writing 2
(Date:7/28/2014)... other forms of dementia, but the research community is ... Washington bioengineers have a designed a peptide structure that ... proteins into a state that,s linked to widespread diseases ... and Lou Gehrig,s disease. The synthetic molecule blocks these ... an abnormally folded form by targeting a toxic intermediate ...
(Date:7/28/2014)... (July 28, 2014) Rice University researchers are ... of varying flexibility that can be used as microscale ... proof that "bead-spring" polymers, introduced as theory in the ... as required and should be of interest to materials ... The work led by Rice chemical and biomolecular engineer ...
(Date:7/28/2014)... many of these due to genetic factors. This is ... which reduce an individual,s ability to reproduce, to disappear ... Science that recently appeared in Nature Communications ... it explain the high rates of male fertility problems, ... of genetic diseases and their treatment. , Various ...
Breaking Biology News(10 mins):New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Seeing is bead-lieving 2Mutations from Venus, mutations from Mars 2
... research by Brown University biologists shows that fruit flies ... the cells that create eggs and sperm. ... Signals from reproductive tissue directly control lifespan and metabolism ... the Proceedings of the National Academy of Sciences, also ...
... deposits of volcanic glass in the western United States ... its present elevation 12 million years ago, roughly 8 ... The finding has implications not only for understanding the ... ancient global climates. "All the global climate models ...
... at the University Hospital of Magdeburg (Germany) have ... dysfunction and oxidative stress followed by the activation ... NF-kB target gene expression in atrial tissue. Their ... of Experimental Biology and Medicine. Multiple tachycardia-associated factors ...
Cached Biology News:Eliminating germline lengthens fly lifespan, Brown study shows 2Sierra Nevada rose to current height earlier than thought, say Stanford geologists 2Sierra Nevada rose to current height earlier than thought, say Stanford geologists 3Sierra Nevada rose to current height earlier than thought, say Stanford geologists 4Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia 2
... operate as a Voltage Clamp, as a Current ... electrophysiology research applications. Performance in any one mode ... • This amazing instrument is ... capabilities of Digital Signal Processing (DSP) integrated circuit ...
... Identical to the DH-2000, but comes with ... switch up to 5 Hz) The ... the continuous spectrum of deuterium and tungsten halogen ... combined-spectrum light source produces a powerful, stable output ...
... in g per ml and is determined from ... of a 1 mg per ml solution. ... agglutinate a 2% suspension of human blood group ... C. Preparation Note: Affinity purified by ...
... The MSD Security ChemStation ... GC/MS software application for ... quantification, library searching and ... aspects of data security, ...
Biology Products: